@author-1788515151757110
启明创投致力于成为中国优秀技术创业者们的首选投资机构
Over the next 5–10 years, more highly original R&D breakthroughs are expected to emerge from Chinese labs and contribute to global pharmaceutical innovation.
A bellwether for China's equity investment industry and a key reference for major institutional LPs when making allocation decisions.
We hope to highlight investment firms that were bolder in their early-stage bets and backed projects that exerted greater influence on their industries and the market at large.
Qiming Venture Partners was one of Biren Technology's earliest and most steadfast supporters. When Biren Technology was founded in 2019, Qiming Venture Partners came in as a founding investor, leading the company's first funding round, and has continued to back the company's growth ever since.
"We won't invest too early before the wave arrives, nor will we follow the crowd once the wave has fully formed. We aim to seize the moment — that 'half-step' just before the big wave hits — to find and back the most promising teams."
The ranking aims to provide a robust evaluation and reference framework for China's equity investment industry.
After completing its investment in Insilico Medicine, Qiming Venture Partners provided the company with sustained support and substantial assistance.
In 2019, Qiming Venture Partners led Insilico Medicine's Series B financing and continued to back the company through its Series C and D rounds. Prior to the IPO, Qiming Venture Partners held approximately 7% of Insilico Medicine's shares, making it one of the company's most important institutional investors.
Select the institutions with outstanding annual performance
Telling the world vivid stories of China's rural revitalization
